CD3E: T-cell surface glycoprotein CD3 epsilon chain
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.
- Drugs that act on it: 7
- Approved: 1
- In phases 1 to 3: 6
- Sponsors: 6
Who Is On It, and How Far Along
Every drug ChEMBL records acting on CD3E, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
- Other
Modalities
Drugs on this target by ChEMBL molecule type.
- Antibody457%
- Other343%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Teplizumab | Approved | Sanofi | Antibody | Other | T-cell surface glycoprotein CD3 epsilon chain other | 10 | — |
| HOKT3 | Phase 3 | — | Other | Inhibitor | T-cell surface glycoprotein CD3 epsilon chain inhibitor | 0 | — |
| Otelixizumab | Phase 3 | GSK | Antibody | Binding agent | T-cell surface glycoprotein CD3 epsilon chain binding agent | 0 | — |
| Visilizumab | Phase 3 | Facet Biotech | Antibody | Inhibitor | T-cell surface glycoprotein CD3 epsilon chain inhibitor | 0 | — |
| Ertumaxomab | Phase 2 | Neovii Biotech | Antibody | Cross-linking agent | T-cell surface glycoprotein CD3 epsilon chain cross-linking agent | 0 | — |
| Resimmune | Phase 2 | Virogen Biotechnology Inc. | Other | Binding agent | T-cell surface glycoprotein CD3 epsilon chain binding agent | 0 | — |
| MEDI-565 | Phase 1 | MedImmune LLC | Other | Cross-linking agent | T-cell surface glycoprotein CD3 epsilon chain cross-linking agent | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Immunodeficiency 18
- 0.74
- Neoplasm
- 0.60
- Plasma cell myeloma
- 0.60
- Type 1 diabetes mellitus
- 0.56
- Small cell lung carcinoma
- 0.56
- Ascites
- 0.51
- Cancer
- 0.50
- T-B- severe combined immunodeficiency
- 0.46
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- CD3E
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1975, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P07766, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets